Skip to main content
Premium Trial:

Request an Annual Quote

Asuragen Raises $18.5M in Series B Financing

NEW YORK (GenomeWeb News) – Asuragen said yesterday that it has raised $18.5 million in Series B financing.
The funding adds to $49 million that the company raised in a Series A round last year.
Investors in the Series B round include PTV Sciences, a new investor, as well as previous investors Telegraph Hill Partners and Growth Capital Partners.
Asuragen is a spinoff of Ambion that was formed after Applied Biosystems acquired Ambion's RNA business in March 2006. It includes Ambion's former diagnostics and services division as well as a discovery group.
In addition to diagnostic research, Asuragen is developing microRNAs as cancer therapeutics and is conducting pre-clinical development of its lead candidates.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.